A Agilent Technologies Inc.

Agilent Again Named to Newsweek’s List of America’s Most Responsible Companies

Agilent Technologies Inc. (NYSE: A) today announced the company is ranked 101 in , up 28 places from 2022. It marks Agilent’s fourth consecutive year on the prestigious list, which includes the best-performing companies based on their environmental, social, and governance (ESG) activities. Agilent also ranked 10 among healthcare and life science companies, up from number 16.

This press release features multimedia. View the full release here:

To formulate the rankings, Newsweek and business intelligence firm Statista, Inc. reviewed corporate social responsibility and financial reports, analyzed quantitative data, and surveyed 13,000 U.S. residents on perceptions of ESG practices. They examined metrics on waste, emissions, energy use, water use, diversity and engagement, philanthropic giving, disclosure and transparency, and economic performance, among others.

“Agilent’s mission is to advance the quality of life,” said Agilent President and CEO Mike McMullen. “Receiving this recognition is gratifying because being a responsible corporate citizen is central to who we are. Focusing on corporate responsibility is woven into the fabric of our business and is part of what we strive to do every day.”

Agilent has reported on its environmental and community impact activities for over 20 years. Agilent further accelerated its environmental commitment in 2021 by adopting science-based targets for reducing emissions by 2030 and achieving .

The company’s most recent showed progress during fiscal year 2021 on a number of critical metrics, including reducing carbon emissions intensity per square foot by 34 percent since 2014, increasing the share of women leaders reporting to the CEO by 30 percent, and achieving industry leading employee engagement levels.

The company released its first Task Force on Climate Related Financial Disclosures (TCFD) report in 2022 and reported on its plan to increase the share of women of color in leadership positions.

Since the release of its 2021 ESG report, Agilent has continued to progress in other areas, including work to advance diversity in STEM education through a , a historically Black university; earning in over 20 countries; and joining the .

The Newsweek ranking adds to other recent recognition of Agilent, including , for instrument recycling and refurbishment, , and .

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in the life sciences, diagnostics, and applied chemical markets, delivering insight and innovation that advance the quality of life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.85 billion in fiscal 2022 and employs 18,000 people worldwide. Information about Agilent is available at . To receive the latest Agilent news, subscribe to the . Follow Agilent on , and .

EN
07/12/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Agilent Technologies Inc.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

 PRESS RELEASE

Agilent xCELLigence RTCA Instrumentation Applied in Recent FDA Approva...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) is pleased to announce its role in supporting Autolus Therapeutics’ , a recently approved CAR T therapy. Agilent's advanced cell analysis instrumentation, specifically the technology, was applied in developing and validating AUCATZYL. The xCELLigence RTCA technology supported the development and implementation of the potency assay. By providing precise and reliable cell analysis solutions, Agilent assisted Autolus in achieving the high standards required for FDA approval. Dr. Xiaobo Wang, Vice President and General Manager of the Cell Functio...

 PRESS RELEASE

CORRECTING and REPLACING Agilent to Showcase Next-Generation Digital P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Please replace the release with the following corrected version due to multiple revisions to the fifth paragraph. The updated release reads: AGILENT TO SHOWCASE NEXT-GENERATION DIGITAL PATHOLOGY SOLUTIONS AT USCAP 2025 (NYSE: A) is excited to announce its participation at the upcoming , which will be held March 22-27, 2025, in Boston. At the conference, Agilent will highlight innovative digital pathology solutions designed to enhance diagnostic accuracy and efficiency. In pathology, Agilent offers comprehensive tissue diagnostic solutions for analyzi...

 PRESS RELEASE

Agilent Research Catalyst Award Presented to Columbia University for P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced that has received an Agilent Research Catalyst (ARC) Award on behalf of , an internationally recognized researcher and physician-scientist specializing in bone marrow transplant (BMT) and cancer cellular immunotherapy. Dr. Muranski is the Director of Cellular Immunotherapy Laboratory at Columbia University Irving Medical Center. He is also an Assistant Professor of Medicine at Columbia University Medical Center, a principal investigator at the Columbia Center for Translational Immunology (CCTI), and a member of the Herbert Irv...

 PRESS RELEASE

Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Com...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced its kit has received two new companion diagnostic indications approvals under EU IVDR1, expanding the eligibility of treatment to early-stage non-small cell lung cancer (NSCLC) and previously untreated advanced melanoma patients. These two new indications bring the total indications launched in Europe for PD-L1 IHC 28-8 pharmDx to nine. PD-L1 IHC 28-8 pharmDx is approved for exclusive use with the advanced staining solution. Lung cancer and malignant melanoma are major healthcare concerns worldwide, with lung cancer accountin...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch